Primate studies demonstrate utility of anti-HIV antibody combination as passive immunotherapy Feb. 13, 2001
Second-generation HIV protease inhibitors retain activity against highly resistant strains Feb. 12, 2001
Highly potent HIV protease inhibitors from Tibotec may prevent class-wide crossresistance Feb. 12, 2001
RSS